TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02795325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PH1
Description: IV infusion of DCR-PH1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCR-PH1
Description: IV infusion of DCR-PH1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00789672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
Study: NCT00731692

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules were administered orally once daily
Study: NCT02297464

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs - 2 per day for breakfast
Description: 11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
Study: NCT03431467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella-CP LV Vent
Description: Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO
Study: NCT02172326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium inhalation capsules for oral inhalation
Description: Powder inhalation via HandiHaler®
Study: NCT04793893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReLex Smile
Description: With the ReLex Smile the optical zone (lenticule diameter) and cap diameter are 6.5 and 7.5 mm respectively. After dissection of both anterior and posterior planes, the lenticule is extracted through 120 degree superior 3.5 mm incision and marked with a sterile marker (ViscotMedster).
Study: NCT01522599

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARDS-Net Strategy
Description: Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECCO2-R
Description: Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
Study: NCT01496781

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemoclip
Description: Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EndoClot
Description: EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
Study: NCT02216227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin
Description: Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Description: Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.~Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery.
Study: NCT03788096

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care Group
Description: Usual care.
Study: NCT01323361

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Laparoscopic ventral hernia repair
Description: Patients operated with laparoscopic repair of ventral or incisional hernia
Study: NCT02743429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dinutuximab beta
Description: Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).~Cycle duration: 35-days.
Study: NCT04133987

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent live attenuated dengue vaccine admixture TV005
Description: The admixtures of the candidate vaccines each contain 4 live attenuated dengue viruses, each of a different serotype.
Study: NCT02939560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroStar® TMS device (Neuronetics, Atlanta, GA)
Description: Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
Study: NCT02216227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: All patients will receive Cefazolin during surgery
Study: NCT04606576

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fish Oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 QD
Description: Oral Insulin once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORMD-0801 BD
Description: Oral Insulin, twice per day
Study: NCT01191580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy
Description: Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy
Description: The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.~Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures.
Study: NCT03899376

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Volumetric modulated arc therapy
Description: VMAT therapy focuses on reducing the dose radiation in adjacent organs at risk

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy
Description: Radiotherapy focus on pelvis area
Study: NCT01170494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol 2000 IU orally, daily
Description: ergocalciferol 2000 IU orally, daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol 25000 IU oraly every 2 weeks
Description: ergocalciferol 25000 IU oraly every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocalciferol 50000 IU orally every 4 weeks
Description: ergocalciferol 50000 IU orally every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ergocal1000 IU & cholecal 1000 IU orally daily
Description: ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol 2000 IU orally daily
Description: cholecalciferol 2000 IU orally everyday

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 25000 IU orally every 2 weeks
Description: Cholecalciferol 25000 IU orally every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 50000 orally every 4 weeks
Description: Cholecalciferol 50000 orally every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo orally everyday
Description: placebo orally everyday
Study: NCT01569958

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
Study: NCT02216227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Povidone Iodine
Description: The purpose of this research is to evaluate a SSI checklist. This checklist includes decolonizing a patient's nose and skin and optimizing antibiotics prior to surgery. At the time that we wrote it, the predominate product to decolonize patient's noses was mupirocin. However, in 2017, an FDA final monograph stated that nasal povidone-iodine may be used for pre-surgical decolonization. Nasal povidone-iodine should be able to overcome barriers to checklist implementation that we identified in Aim 3. We now plan to replace the nasal agent mupirocin with the nasal agent povidone-iodine at 3 participating medical centers (Iowa City VA, Minneapolis VA and Portland VA) to assess whether this overcomes the barriers to our SSI checklist.
Study: NCT01684085

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Explanation encouraging sleep
Description: An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Explanation discouraging sleep
Description: An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
Study: NCT04133987

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PLASMA-LYTE A Injection pH 7.4 (Multiple Electrolytes Injection, Type 1, USP) is a sterile, nonpyrogenic isotonic solution in a single dose container for intravenous administration.
Study: NCT04267432

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank
Study: NCT01569958

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 1 mA stimulation for 30 seconds every 900 seconds per session
Study: NCT03002012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: sertraline 400mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: matched placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluconazole
Description: Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
Study: NCT04426331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher Without Value Information
Description: Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital. The voucher included the patient's name, the screener's name, and an expiration date 90 days from the date of screening.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. So, with this voucher, both the exam and the glasses will be completely free.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voucher With Value Information
Description: Patients being referred for follow-up received standard materials, counseling, and reminders as in the 'no information' group and were provided with a physical voucher they were told is redeemable for free follow-up appointment at Johns Hopkins Hospital, which would normally cost $250. The voucher included the patient's name, the screener's name, an expiration date 90 days from the date of screening, and a statement about the $250 voucher value.~These participants were told: I am going to give you this voucher for a completely free appointment and a free pair of glasses if you need them. These services normally cost about $250, but with this voucher, both the exam and the glasses will be completely free.
Study: NCT05840146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: Two I-strips were used:~1. The first-third of one I-strip began at the posterior iliac crest, without tension as an anchor. Then the patient actively flexed and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.~2. The first-third of the second I-strip was applied starting at the anterior iliac crest, without tension as an anchor. The patient actively extended and adducted the affected hip, thus, the middle-third of the tape was applied with approximately 50% tension. Then the hip was set in its original position and the last-third of the tape ended approximately greater trochanter without tension.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: A single I-strip without tension in tape or muscle stretch. After paper backing was completely removed, tape was essentially placed on the skin across the lateral side of the hip.
Study: NCT03326492

Intervention type: DRUG
Intervention: Antivenom serum Inoserp Pan-Africa® injection
Description: Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
Study: NCT00854945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na
Description: 1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
Study: NCT00105703

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Case management using advanced nurse practitioners
Study: NCT01923415

Intervention type: PROCEDURE
Intervention: No intervention, skin biopsy
Description: All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).

Intervention type: PROCEDURE
Intervention: No intervention, skin biopsy
Description: All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).

Intervention type: PROCEDURE
Intervention: No intervention, skin biopsy
Description: All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).

Intervention type: PROCEDURE
Intervention: No intervention, blood collection
Description: Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.

Intervention type: PROCEDURE
Intervention: No intervention, blood collection
Description: Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.

Intervention type: PROCEDURE
Intervention: No intervention, blood collection
Description: Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.

Intervention type: PROCEDURE
Intervention: No intervention, urine collection
Description: Urine will be collected from all participants.

Intervention type: PROCEDURE
Intervention: No intervention, urine collection
Description: Urine will be collected from all participants.

Intervention type: PROCEDURE
Intervention: No intervention, urine collection
Description: Urine will be collected from all participants.
Study: NCT01413360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose vitamin C
Description: Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
Study: NCT04045496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-3312
Description: JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.
Study: NCT04267432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TCI633
Description: Probiotics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Type 2 collagen
Description: Positive control group
Study: NCT00815438

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cholecystectomy.
Description: Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
Study: NCT04682626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soft gelatin capsules each contains 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
Description: Soft gelatin capsules each contain 50 000 IU VD3 (cholecalciferol) equivalents to 1.25 mg.
Study: NCT00382954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: I.V., 8, or 10 or 12 mg/m\^2 weekly (days 1, 8, 15, and 22) for 4 weeks
Study: NCT00457509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A/H5N1 inactivated, split-virion influenza vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03263208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: CD19 CAR-T cells will be administered after completion of the chemotherapy.
Study: NCT02121483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin medium dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin low dose
Study: NCT01768351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Zemplar cp 1 mcg/day per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Rocaltrol cp 0,5 mcg every other day per os
Study: NCT04567875

Intervention type: OTHER
Intervention: No Intervention on patients
Description: No Intervention on patients
Study: NCT00818428

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech Production Intervention
Description: Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Production Intervention
Description: Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Perception Intervention
Description: Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech Perception Intervention
Description: Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Articulation Parent Group
Description: Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
Study: NCT01684085

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam 1 mg
Study: NCT00531466

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tolperisone HCl (AV650)
Description: One tablet orally three times a day for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One tablet orally three times a day for 28 days
Study: NCT02220608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Study: NCT01840566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide